Needham Maintains Buy on Veracyte, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on Veracyte and raises the price target from $31 to $37.
August 28, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reaffirmed a Buy rating for Veracyte and increased the price target from $31 to $37, indicating a positive outlook for the stock.
The increase in the price target from $31 to $37 by a reputable analyst suggests a positive outlook for Veracyte's stock, likely leading to a short-term price increase. The Buy rating further supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100